GlaxoSmithKline Pharmaceuticals Limited has initiated a postal ballot process to secure shareholder approval for key leadership transitions, including the re-appointment of its Managing Director and the addition of a new Non-Executive Director to its board.

The company’s Board of Directors approved the resolutions on August 3, 2026. Shareholders will vote via remote e-voting between August 14 and September 13, 2026. The results are expected to be announced by September 15, 2026.

Leadership Changes

The ballot seeks approval for two ordinary resolutions:

• Appointment of Karine J F Natland: Ms. Natland, currently SVP Asia Pacific at GSK, was appointed as an Additional Director on August 4, 2026. She will serve as a Non-Executive Director liable to retire by rotation. She brings over 20 years of experience in the pharmaceutical industry, having previously held senior roles at Organon, Merck & Co, and MSD.

• Re-appointment of Bhushan Akshikar: Mr. Akshikar, who has served as Managing Director since 2022, is set for re-appointment for a two-year term from December 1, 2026, to November 30, 2028. He has been with GSK since 2011 and previously spent 15 years with Johnson & Johnson.

Remuneration Structure

Mr. Akshikar’s proposed remuneration package includes a basic salary not exceeding ₹2.4 crore per month. His total compensation also comprises:

• A performance bonus capped at 100% of his salary, based on innovation sales, sales, profit, and cash flow.
• Long-term incentives including share value plans, share option plans, and performance shares.
• Perquisites such as rent-free accommodation or house rent allowance up to 50% of monthly salary, medical insurance, and club fees.

The aggregate value of perquisites and allowances is restricted to 2.5 times his annual salary. As of March 31, 2026, Mr. Akshikar’s total remuneration stood at ₹11.36 crore.

Voting Process

The e-voting facility is provided by KFin Technologies Limited. Only shareholders registered in the Register of Members or Depositories as of the cut-off date, August 7, 2026, are eligible to vote. P.N. Parikh of Parikh & Associates has been appointed as the Scrutinizer to ensure a fair and transparent voting process.

Key Dates

Ms. Natland holds an executive dual MBA from the Norwegian School of Management and ECSP, Paris, and a bachelor’s degree in pharmacy. Mr. Akshikar holds an MBA in Marketing from SPJIMR and a bachelor’s degree in Pharmaceutical Sciences from the University of Pune.

GlaxoSmithKline Pharmaceuticals reported a 24% year-on-year increase in standalone profit after tax (PAT) to ₹253.33 crore for the quarter ended June 30, 2026 (Q1FY27), driven by robust revenue growth of 15% to ₹924.42 crore. The Mumbai-based pharmaceutical major also announced key leadership changes, appointing Karine J F Natland as a Non-Executive Director while re-appointing Bhushan Akshikar as Managing Director for a two-year term starting December 1, 2026. The strong top-line momentum was underpinned by continued progress in the company’s portfolio transformation strategy and favorable base effects from the comparable period last year.

The Board of Directors approved the unaudited standalone and consolidated financial results on August 3, 2026, in compliance with Regulation 33 read with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015. Statutory auditors Deloitte Haskins & Sells LLP conducted a limited review of the interim financial information. Consolidated net profit rose 15.7% to ₹2,371.8 crore, while consolidated revenue grew 16.5% to ₹9,384.4 crore.

Financial Performance Highlights

Standalone revenue from operations reached ₹924.42 crore in Q1FY27, up from ₹804.83 crore in the corresponding period of FY26. Standalone PAT increased to ₹253.33 crore from ₹204.70 crore previously. The company’s operating efficiency remained strong, with standalone EBITDA margins holding at approximately 32%. Consolidated metrics showed broader group strength, with consolidated revenue rising to ₹9,384.4 crore and consolidated net profit reaching ₹2,371.8 crore.

Portfolio Performance Drivers

The General Medicines portfolio demonstrated strong growth, with the top five promoted brands outperforming the market (Evolution Index >100). Key brands such as Augmentin, Ceftum, and T-Bact reinforced their leadership positions through deeper scientific engagement and omnichannel execution. The Respiratory portfolio saw traction for Trelegy Ellipta via new access pathways, while Nucala (mepolizumab) continued to benefit patients with chronic respiratory diseases.

The Vaccines business maintained its leadership in the self-pay private paediatric vaccines market, led by Infanrix Hexa and Fluarix Tetra. In adult vaccinations, focus on elderly patient cohorts with Cardiovascular and Metabolic Diseases drove higher uptake of Shingrix. The Oncology business, launched in August 2025, grew significantly with specialized therapies Jemperli (dostarlimab) and Zejula (niraparib), establishing Jemperli as the leading immunotherapy for first-line primary advanced endometrial cancer.

Leadership Changes

The board welcomed Karine J F Natland as a Non-Executive Director effective August 3, 2026. Natland, currently SVP Asia Pacific at GSK, leads product strategy for the General Medicines business. Subesh Williams stepped down from the board on the same date due to other professional commitments. Bhushan Akshikar was re-appointed as Managing Director for a two-year term commencing December 1, 2026, continuing to oversee operations in India, Africa, and the Middle East.

What the Numbers Show

The divergence between standalone PAT growth (24%) and consolidated PAT growth (15.7%) highlights the distinct performance dynamics within the group structure. While standalone results reflect the core Indian operations' efficiency and brand strength, consolidated figures incorporate broader group synergies and subsidiary performances. The strong Evolution Index (>100) for top General Medicines brands indicates that GSK India is not just growing with the market but actively gaining share through scientific differentiation and execution excellence.